{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:26:52Z","timestamp":1793424412414,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T15:01:16Z","timestamp":1724511676000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-994X","authenticated-orcid":false,"given":"Enrico","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0228-9421","authenticated-orcid":false,"given":"Silvia","family":"Girotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-148X","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-0963","authenticated-orcid":false,"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.08.002_bib0001","doi-asserted-by":"crossref","first-page":"m3434","DOI":"10.1136\/bmj.m3434","article-title":"Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study","author":"Hwang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2024.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.7326\/M23-0623","article-title":"Regulatory review duration and differences in submission times of drugs in the United States and Europe, 2011 to 2020","volume":"176","author":"Vokinger","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcf.2024.08.002_bib0003","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.08.002_bib0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.08.002_bib0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcf.2024.08.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0124-2017","article-title":"A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators","volume":"27","author":"Ponzano","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcf.2024.08.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.07.006","article-title":"Traits, trends and hits of orphan drug designations in cystic fibrosis","author":"Costa","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMc1700103","article-title":"Regulatory review of new therapeutic agents - FDA versus EMA, 2011-2015","volume":"376","author":"Downing","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.08.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010-2019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcf.2024.08.002_bib0010","unstructured":"US Food and Drug Administration. Drugs@FDA n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed February 8, 2024)."},{"key":"10.1016\/j.jcf.2024.08.002_bib0011","unstructured":"The European Medicines Agency n.d. https:\/\/www.ema.europa.eu\/en\/medicines (accessed February 8, 2024)."},{"key":"10.1016\/j.jcf.2024.08.002_bib0012","unstructured":"The European Medicines Agency. The evaluation of medicines, step-by-step. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/evaluation-medicines-step-step. Accessed: 06\/02\/2024 n.d."},{"key":"10.1016\/j.jcf.2024.08.002_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.107.1.1","article-title":"Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group","volume":"107","author":"Farrell","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2024.08.002_bib0014","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1377\/hlthaff.2011.0231","article-title":"Despite criticism of the fda review process, new cancer drugs reach patients sooner in the United States Than In Europe","volume":"30","author":"Roberts","year":"2011","journal-title":"Health Aff"},{"key":"10.1016\/j.jcf.2024.08.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103342","article-title":"Emergent treatments for \u03b2-thalassemia and orphan drug legislations","volume":"27","author":"Costa","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcf.2024.08.002_bib0016","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/bloodadvances.2023011730","article-title":"Successes and pitfalls in orphan drug development for sickle cell disease","volume":"8","author":"Costa","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcf.2024.08.002_bib0017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jcf.2020.05.011","article-title":"Building global development strategies for cf therapeutics during a transitional cftr modulator era","volume":"19","author":"Mayer-Hamblett","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.08.002_bib0021","unstructured":"The European Medicines Agency and Health technology assessment bodies. n.d. https:\/\/www.ema.europa.eu\/en\/partners-networks\/health-technology-assessment-bodies (accessed February 17, 2024)."},{"key":"10.1016\/j.jcf.2024.08.002_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-019-1078-5","article-title":"Comparing access to orphan medicinal products in Europe","volume":"14","author":"Zamora","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcf.2024.08.002_bib0023","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jcf.2016.05.007","article-title":"Cystic fibrosis in Latin America\u2014Improving the awareness","volume":"15","author":"Silva Filho","year":"2016","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:10Z","timestamp":1738275070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324008282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324008282"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}